Raze’s pioneering approach prevents cancer cells from engaging the metabolic pathways that provide the basic building materials necessary for cancer’s growth and survival.

Our pipeline of therapeutic programs is built on:

  • Proprietary biological insight into 1C metabolism and its role in specific solid and hematologic malignancies
  • Proprietary metabolite flux and metabolomic assays
  • Novel biochemistry, assays and medicinal chemistry
  • Rapid and rational translation of our discoveries into the clinic in precisely defined patient populations using biomarker-driven drug development

These targets form the basis for Raze’s active and growing development pipeline.